Sort   by:  
 Page size 
UnknownSafety and Clinical Activity of SHR7390 Monotherapy or Combined With Camrelizumab for Advanced Solid Tumor: Results From Two Phase I Trials.
Not available
S-EPMC9847543 | biostudies-literature
UnknownEfficacy and safety of camrelizumab plus famitinib in patients with previously treated non-small-cell lung cancer: a single-arm, phase II trial.
Not available
S-EPMC11694305 | biostudies-literature
UnknownTegileridine for moderate-to-severe acute pain following abdominal surgery: A randomized, double-blind, phase 3 clinical trial.
Not available
S-EPMC12765830 | biostudies-literature
UnknownSHR2285, the first selectively oral FXIa inhibitor in China: Safety, tolerability, pharmacokinetics and pharmacodynamics combined with aspirin, clopidogrel or ticagrelor.
Not available
S-EPMC9626527 | biostudies-literature
UnknownFirst-line treatment with camrelizumab plus famitinib in advanced or metastatic NSCLC patients with PD-L1 TPS ≥1%: results from a multicenter, open-label, phase 2 trial.
Not available
S-EPMC10882294 | biostudies-literature
UnknownEvaluation of the pharmacokinetic interactions of montmorillonite powder or loperamide on pyrotinib in healthy volunteers.
Not available
S-EPMC12104674 | biostudies-literature
UnknownCamrelizumab plus carboplatin and pemetrexed as first-line therapy for advanced non-squamous non-small-cell lung cancer: 5-year outcomes of the CameL randomized phase 3 study.
Not available
S-EPMC11603811 | biostudies-literature
UnknownFuzuloparib with or without apatinib as maintenance therapy in newly diagnosed, advanced ovarian cancer (FZOCUS-1): A multicenter, randomized, double-blind, placebo-controlled phase 3 trial.
Not available
S-EPMC12645347 | biostudies-literature
UnknownA Novel CD73 Inhibitor SHR170008 Suppresses Adenosine in Tumor and Enhances Anti-Tumor Activity with PD-1 Blockade in a Mouse Model of Breast Cancer.
Not available
S-EPMC8403083 | biostudies-literature
UnknownPharmacokinetics and bioavailability of a new long-acting insulin analog in healthy Chinese volunteers: an open, randomized, single-dose, two-period and two-sequence cross-over study.
Not available
S-EPMC10770825 | biostudies-literature
Sort   by:  
 Page size